Podcast: The Global Generics & Biosimilars Awards 2024

All The Details Of Our Latest Ceremony, This Year Taking Place On 9 October In Milan

In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.

Generic Bulletin Podcast
The GGB Awards 2024 will take place on 9 October in Milan

The Global Generics & Biosimilars Awards is now in its eleventh year. In this podcast, Generics Bulletin editors Dave Wallace and Dean Rudge talk about how you can enter and attend the awards – both of which remain free of charge – as well as offering tips for entries and discussing the reasons why off-patent industry players might want to be involved in the event. 

Citeline · 2024 Global Generics & Biosimilars Awards

Open Media

Entries for the Global Generics & Biosimilars Awards 2024 are open until Monday 22 July and can cover any activities undertaken between 1 September 2023 and 31 July 2024. Our prizegiving ceremony will then take place in-person at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week.

Backed by headline sponsor IQVIA, category sponsors include Cerba Research for Company of the Year – Americas, as well as Pharmacloud for our Leader of the Year category.

The awards are also supported by International Health Partners in our corporate social responsibility initiative of the year category. Our 2024 supporters also include the International Generic and Biosimilars Medicines Association.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail Casey.Burwell@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail Jo.Kirkpatrick@citeline.com

More from Generics

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 

Generics Bulletin reviews global regulatory developments across the world.

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

 
• By 

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.

Tevogen Launches Generics-Focused Initiative As Trump Eyes Pharma Tariffs

 
• By 

As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By 

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

More from Products

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 

Generics Bulletin reviews global regulatory developments across the world.

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

 
• By 

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.

Tevogen Launches Generics-Focused Initiative As Trump Eyes Pharma Tariffs

 
• By 

As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.